OBJECTIVE: To investigate the risk factors for recurrence of medulloblastoma (MB) within 2 years and their influence on progression-free survival (PFS). METHODS: A retrospective analysis was performed for the clinical data of 123 children with MB who were admitted from January to December, 2017. According to the presence or absence of recurrence, they were divided into recurrence group with 30 children and non-recurrence group with 93 children. The risk factors for recurrence within 2 years were analyzed, and PFS was compared between the children with different risk factors. RESULTS: Large-cell/anaplastic type and M stage were risk factors for MB recurrence within 2 years. The risk of recurrence in the children with M+ MB was 3.525 times that in those with M0 MB, and the risk of recurrence in the children with large-cell/anaplastic MB was 3.358 times that in those with classic MB (P<0.05). The survival analysis showed that the median PFS time was 20 months in the children with M+ MB, and the 20-month PFS rate was 50% ± 11% in the children with M+ MB and 81% ± 5% in those with M0 MB (P<0.05). The 20-month PFS rate was 80% ± 5% in the children with classic MB, 65% ± 10% in those with desmoplastic/nodular MB, 86% ± 13% in those with MB with extensible nodularity, and 36% ± 20% in those with large-cell/anaplastic MB (P<0.05). CONCLUSIONS: Recurrence is an important influencing factor for the prognosis of MB, and M+ stage and large-cell/anaplastic MB are risk factors for recurrence. Children with such risk factors tend to have a low PFS rate.
OBJECTIVE: To investigate the risk factors for recurrence of medulloblastoma (MB) within 2 years and their influence on progression-free survival (PFS). METHODS: A retrospective analysis was performed for the clinical data of 123 children with MB who were admitted from January to December, 2017. According to the presence or absence of recurrence, they were divided into recurrence group with 30 children and non-recurrence group with 93 children. The risk factors for recurrence within 2 years were analyzed, and PFS was compared between the children with different risk factors. RESULTS: Large-cell/anaplastic type and M stage were risk factors for MB recurrence within 2 years. The risk of recurrence in the children with M+ MB was 3.525 times that in those with M0 MB, and the risk of recurrence in the children with large-cell/anaplastic MB was 3.358 times that in those with classic MB (P<0.05). The survival analysis showed that the median PFS time was 20 months in the children with M+ MB, and the 20-month PFS rate was 50% ± 11% in the children with M+ MB and 81% ± 5% in those with M0 MB (P<0.05). The 20-month PFS rate was 80% ± 5% in the children with classic MB, 65% ± 10% in those with desmoplastic/nodular MB, 86% ± 13% in those with MB with extensible nodularity, and 36% ± 20% in those with large-cell/anaplastic MB (P<0.05). CONCLUSIONS: Recurrence is an important influencing factor for the prognosis of MB, and M+ stage and large-cell/anaplastic MB are risk factors for recurrence. Children with such risk factors tend to have a low PFS rate.
Authors: Carl Koschmann; Karina Bloom; Santhosh Upadhyaya; J Russell Geyer; Sarah E S Leary Journal: J Pediatr Hematol Oncol Date: 2016-05 Impact factor: 1.289
Authors: Amar Gajjar; Murali Chintagumpala; David Ashley; Stewart Kellie; Larry E Kun; Thomas E Merchant; Shaio Woo; Greg Wheeler; Valerie Ahern; Matthew J Krasin; Maryam Fouladi; Alberto Broniscer; Robert Krance; Gregory A Hale; Clinton F Stewart; Robert Dauser; Robert A Sanford; Christine Fuller; Ching Lau; James M Boyett; Dana Wallace; Richard J Gilbertson Journal: Lancet Oncol Date: 2006-10 Impact factor: 41.316
Authors: R D Kortmann; J Kühl; B Timmermann; U Mittler; C Urban; V Budach; E Richter; N Willich; M Flentje; F Berthold; I Slavc; J Wolff; C Meisner; O Wiestler; N Sörensen; M Warmuth-Metz; M Bamberg Journal: Int J Radiat Oncol Biol Phys Date: 2000-01-15 Impact factor: 7.038
Authors: J Verlooy; V Mosseri; S Bracard; A Lellouch Tubiana; C Kalifa; F Pichon; D Frappaz; P Chastagner; A Pagnier; A-I Bertozzi; J C Gentet; E Sariban; X Rialland; C Edan; D Bours; M Zerah; C Le Gales; C Alapetite; F Doz Journal: Eur J Cancer Date: 2006-09-07 Impact factor: 9.162
Authors: Paul A Northcott; Andrey Korshunov; Hendrik Witt; Thomas Hielscher; Charles G Eberhart; Stephen Mack; Eric Bouffet; Steven C Clifford; Cynthia E Hawkins; Pim French; James T Rutka; Stefan Pfister; Michael D Taylor Journal: J Clin Oncol Date: 2010-09-07 Impact factor: 44.544
Authors: Stefan Rutkowski; Katja von Hoff; Angela Emser; Isabella Zwiener; Torsten Pietsch; Dominique Figarella-Branger; Felice Giangaspero; David W Ellison; Maria-Luisa Garre; Veronica Biassoni; Richard G Grundy; Jonathan L Finlay; Girish Dhall; Marie-Anne Raquin; Jacques Grill Journal: J Clin Oncol Date: 2010-10-12 Impact factor: 44.544